Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wali, R. K.
Right arrow Articles by Bissonnette, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wali, R. K.
Right arrow Articles by Bissonnette, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 20, No. 12, 2355-2360, December 1999
© 1999 Oxford University Press


Short Communications

Inhibition of O6-methylguanine-DNA methyltransferase increases azoxymethane-induced colonic tumors in rats

Ramesh K. Wali, Susan Skarosi, John Hart1, Yingchun Zhang1, M.eileen Dolan, Robert C. Moschel2, Lan Nguyen, Reba Mustafi, Thomas A. Brasitus and Marc Bissonnette3

Department of Medicine and
1 Department of Pathology, University of Chicago, Chicago, IL 60637 and
2 Carcinogen-Modified Nucleic Acid Chemistry, ABL-Basic Research Program, NCI–FCRDC, Frederick, MD, USA

Azoxymethane (AOM) causes O6-methylguanine adduct formation which leads to G->A transitions. Their repair is carried out by O6-methylguanine-DNA methyltransferase (MGMT). To evaluate the importance of this repair event in AOM-induced carcinogenesis, we examined the effect of O6-benzylguanine (BG), a potent inhibitor of MGMT, on colonic tumor development. Rats were treated weekly for 2 weeks at 0 and 24 h with BG (60 mg/kg body wt i.p.) or vehicle (40% polyethylene glycol, PEG-400), followed 2 h after the first dose of BG with AOM (15 mg/kg body wt) or vehicle (saline) i.p. Rats were killed 35 weeks later and tumors harvested and DNA extracted. In the AOM-treated groups, BG caused a significant increase in tumor incidence with tumors in 65.9%, versus 30.8% in the AOM/PEG-treated group (P < 0.05). In the BG/AOM group there was also a significant increase in tumor multiplicity, with 2.3 tumors/tumor-bearing rat, versus 1.6 tumors/tumor- bearing rat in the AOM/PEG group (P < 0.05). Since O6-methylguanine adducts can cause activating mutations in the K-ras and ß-catenin genes, we examined the effects of BG on these mutations. In the BG group there were seven mutations in codon 12 or 13 of exon 1 of the K-ras gene in 51 tumors examined, compared with no K-ras mutations in 17 tumors analyzed in the AOM/PEG group (P = 0.12). In the BG/AOM group there were 10 mutations in exon 3 of the ß-catenin gene among 48 tumors evaluated, compared with six mutations in 16 tumors analyzed in the PEG/AOM group (P = 0.16). In summary, MGMT inhibition increases AOM-induced colonic tumor incidence and multiplicity in rats.

Abbreviations: AOM, azoxymethane; ASOH, allele-specific oligonucleotide hybridization; BG, O6-benzylguanine; MGMT, O6-methylguanine-DNA methyltransferase; PEG, polyethylene glycol; PM-RFLP, primer-mediated restriction fragment length polymorphism; SSCP, single strand conformational polymorphism.

3 To whom correspondence should be addressed at: Department of Medicine, MC 4076, University of Chicago Hospitals and Clinics, 5841 South Maryland Avenue, Chicago, IL 60637, USA Email: mbissonn{at}medicine.bsd.uchicago.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
C. H.F. Chan, D. Cook, and C. P. Stanners
Increased colon tumor susceptibility in azoxymethane treated CEABAC transgenic mice
Carcinogenesis, September 1, 2006; 27(9): 1909 - 1916.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Khare, S. Cerda, R. K. Wali, F. C. von Lintig, M. Tretiakova, L. Joseph, D. Stoiber, G. Cohen, K. Nimmagadda, J. Hart, et al.
Ursodeoxycholic Acid Inhibits Ras Mutations, Wild-type Ras Activation, and Cyclooxygenase-2 Expression in Colon Cancer
Cancer Res., July 1, 2003; 63(13): 3517 - 3523.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. Takagi, Y. Nakano, S. Takekoshi, T. Inagami, and M. Tamura
Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis
Carcinogenesis, July 1, 2002; 23(7): 1235 - 1241.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Y. Hong, R. S. Chapkin, J. S. Morris, N. Wang, R. J. Carroll, N. D. Turner, W. C. L. Chang, L. A. Davidson, and J. R. Lupton
Anatomical site-specific response to DNA damage is related to later tumor development in the rat azoxymethane colon carcinogenesis model
Carcinogenesis, November 1, 2001; 22(11): 1831 - 1835.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. A. Peterson, N. M. Thomson, D. L. Crankshaw, E. E. Donaldson, and P. J. Kenney
Interactions between Methylating and Pyridyloxobutylating Agents in A/J Mouse Lungs: Implications for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced Lung Tumorigenesis
Cancer Res., August 1, 2001; 61(15): 5757 - 5763.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. M. Kokkinakis, R. M. Hoffman, E. P. Frenkel, J. B. Wick, Q. Han, M. Xu, Y. Tan, and S. C. Schold
Synergy between Methionine Stress and Chemotherapy in the Treatment of Brain Tumor Xenografts in Athymic Mice
Cancer Res., May 1, 2001; 61(10): 4017 - 4023.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
D. M. Kokkinakis, D. B. Bocangel, S. C. Schold, R. C. Moschel, and A. E. Pegg
Thresholds of O6-Alkylguanine-DNA Alkyltransferase which Confer Significant Resistance of Human Glial Tumor Xenografts to Treatment with 1,3-Bis(2-chloroethyl)-1-nitrosourea or Temozolomide
Clin. Cancer Res., February 1, 2001; 7(2): 421 - 428.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.